Reason for request
The AB of VONCENTO is :
- substantial in the indication: “von Willebrand disease (VWD): Treatment of bleeding episodes or prevention and treatment of surgical bleeding in patients with von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.”
- insufficient in the indication “Haemophilia A (congenital factor VIII deficiency) : Prophylaxis and treatment of bleeding in patients with haemophilia A.
Clinical Added Value
|no clinical added value||
VONCENTO does not provide any improvement in actual benefit (IAB V, non-existent) in the current management of von Willebrand disease.
Haemophilia A : Not applicable